Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.58 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9122257 | 0.99 | ADORA1 (1.00) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL7028224 | 0.93 | ADORA1 (0.87) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL7028598 | 0.92 | ADORA1 (0.88) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL8836691 | 0.88 | ADORA1 (0.79) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL10815381 | 0.81 | ADORA1 (0.67) | ADORA1MEN1KMT2ATSHRSIRT1 | |
| SCHEMBL7025747 | 0.78 | ADORA1 (0.64) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL7025779 | 0.77 | ADORA1 (0.65) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL7032150 | 0.76 | ADORA1 (0.64) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL1063544 | 0.76 | SIRT1 (0.68) | ADORA1MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL9546979 | 0.76 | SIRT1 (0.68) | ADORA1MEN1KMT2AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815446-B1 | ADMINISTERING 8-AMINO-XANTHINE DERIVATIVE AS ANTIASTHMATIC OR ANTIDIARRHEA AGENT | VANDERBILT UNIVERSITY | 2004-11-09 | — | — | US | disclosed |
| US-6806270-B2 | XANTHINE DERIVATIVES, SUCH AS 3-ISOBUTYL-8-PYRROLIDINYLXANTHINE; TREATING ASTHMA, DIARRHEA, ETC. | VANDERBILT UNIVERSITY | 2004-10-19 | — | — | US | disclosed |
| US-20030087904-A1 | Selective antagonists of A2B adenosine receptors | VANDERBILT UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| EP-1208100-B1 | SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | UNIV VANDERBILT (US) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087904-A1 | Selective antagonists of A2B adenosine receptors | ADORA2B, ADORA1, ADORA2A | ADORA1 2/4885MEN1 3952/4885KMT2A 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.